Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

On the fifth and final day of the ACCC 37th [Virtual] National Oncology Conference, speakers and attendees addressed the disproportionate representation of women in oncology. In their opening remarks to the keynote address, Nadine J. Barrett, PhD, MA, MS, ACCC Board of Trustees Member, and Krista Nelson, MSW, LCSW, OSW-C, BCD, ACCC President-Elect, discussed the potential irony of having a man present …
Advocacy Organization Landscape Assessment: Liver Cancer Resources Phase II May 2019 Advocacy Organization Landscape Assessment: Liver Cancer Resources ​ Table of Contents 2. Summary 4. Liver Cancer Resource Distribution: For Patients 5. Liver Cancer Resource Distribution: For HCP/Scientists 6. American Association …
Day 4 of the ACCC 37th [Virtual] National Oncology Conference gave participants the opportunity to connect directly with this year’s ACCC Innovator Award winners and their physician and/or administrative champions. These leaders shared with conference attendees what led them to support their innovations, how they procured the necessary buy-in and resources to implement those innovations, and what their …
To better understand the challenges oncology social workers face when giving patients the care and resources they need in their battle against cancer, the Association of Community Cancer Centers is collaborating with the University of Michigan School of Social Work and the Association of Oncology Social Work (AOSW) to conduct the Oncology Social Work Competencies, Opportunities, Roles, and Expertise …
2020 ACCC Innovator Awards: Making Outpatient Chemo Possible August 6, 2020 To improve patient care and reduce overall costs, the University of Arizona Cancer Center at Banner University Medical Center in Tucson—ACCC Innovator Award winner— transitioned to delivering select chemotherapies in its ambulatory clinics. Doing so took a significant coordinated effort. The task of assessing which chemotherapies …
Access to Care Policy Project Action on many of today’s most pressing public policy issues in oncology are happening at the state and local level. Some of this is because of legislative gridlock at the federal level, although much is due to the enduring notion that healthcare—and particularly cancer care—is best regulated locally. Today, healthcare policy is among the most hotly debated issues in …
Advocacy in Action: Putting Guardrails Around Step Therapy Step therapy, also known as “fail first” therapy, requires patients to try (and “fail”) one or more lower-cost medications before the insurance plan will cover the drug originally prescribed by a patient’s physician. This "fail first" requirement is problematic, causing unnecessary delays in care and increased anxiety in patients waiting for …
2020 ACCC Innovator Awards: Reducing Readmissions After Chemotherapy July 9, 2020 Quality measure OP-35—the first chemo-specific measure in the Centers for Medicare & Medicaid Services Hospital Outpatient Quality Reporting Program—went into effect for payment determination this year. To be fully prepared, Mercy Cancer Care—ACCC Innovator Award winner—looked at 90,000 of their qualifying chemotherapy …
2020 ACCC Innovator Awards: Creating a Community-Based Cardio-Oncology Clinic July 14, 2020 In 2016, Vijay Rao, MD, PhD, was working as a cardiologist at Franciscan Health—ACCC Innovator Award winner—in Indianapolis, Indiana, when three of his female patients in treatment for breast cancer all suffered heart failure. Newly committed to proactively addressing the link between oncology treatments …
Major Movement on Several Key Pieces of Legislation We are excited to announce the recent healthcare legislation signed into law by the Governor of Louisiana. These laws are aimed at improving the healthcare landscape in the state and bringing about positive changes for patients. Let's take a closer look at each of these important bills: SB98 - Bone Marrow Donation Effective Date: July …
Biomarker Testing: Allowing Individualized Treatment for Cancer Patients March 2022 Biomarker testing has become an incredible tool in helping doctors identify the right treatment options for a patient. Specifically, oncologists are using it as a first step in identifying which medications might work for a cancer patient. Precision medicine can provide targeted treatment and a better chance of …
Jump to news releases: 2021 2020 2019 2018 2017 2016 2015 2014 2013
For more information on any of the news releases here, please contact: Tricia O’Mahen Dickey Associate Director, Marketing tdickey@accc-cancer.org
The Association of Community Cancer Centers (ACCC) mourns the passing of Justice Ruth Bader Ginsburg, who died on Friday, September 18, at age 87 due to complications from metastatic pancreatic cancer. Along with being a distinguished jurist, Justice Ginsburg was, like her mother, a cancer patient. Diagnosed with cancer five times over the past 21 years, Justice Ginsburg had undergone multiple …
© 2020 sanofi-aventis U.S. LLC. All rights reserved. MAT-US-2017236 08/20 References: 1. Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Decisions. https://www.cms.gov/files/ document/2020-hcpcs-application-summary-quarter-2-2020-drugs-and-biologicals.pdf. Accessed July 23, 2020. 2. SARCLISA [package insert]. …
Chelsea Osterman, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC View Poster
THYROID CANCER TESTING PROGRAM NO PATIENT, HEALTHCARE PROGRAM, PAYER, OR BENEFICIARY SHALL BE BILLED FOR ANY TEST ORDERED PURSUANT TO THE THYROID CANCER TESTING PROGRAM. *Eligible patient may receive either one (1) NGS thyroid profile test (for MTC) or one (1) NGS thyroid profile plus RET FISH test (for non-MTC), regardless of test results or treatment decision. No patient, healthcare …
Joanna Young, DO, Levine Cancer Institute, Atrium Health, Charlotte, NC View Poster
Eligible patients (US-based only) may receive either one (1) NGS Thyroid Profile test (for advanced or metastatic medullary thyroid cancer (“MTC”) patients 12 years of age and older who require systemic therapy) or one (1) NGS Thyroid Profile plus RET FISH test (for advanced or metastatic non-medullary thyroid cancer (“non-MTC”) patients 12 years of age and older who require systemic therapy and …
Emeka Uzoka, MD, Department of Internal Medicine, East Carolina University, Greenville, NC View Poster